Cosmo Pharmaceuticals NV (XSWX:COPN) Debt-to-Equity : 0.41 (As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Cosmo Pharmaceuticals NV Debt-to-Equity?

Cosmo Pharmaceuticals NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was CHF169.9 Mil. Cosmo Pharmaceuticals NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was CHF1.4 Mil. Cosmo Pharmaceuticals NV's Total Stockholders Equity for the quarter that ended in Jun. 2023 was CHF420.7 Mil. Cosmo Pharmaceuticals NV's debt to equity for the quarter that ended in Jun. 2023 was 0.41.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cosmo Pharmaceuticals NV's Debt-to-Equity or its related term are showing as below:

XSWX:COPN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.2 Max: 0.45
Current: 0.41

During the past 13 years, the highest Debt-to-Equity Ratio of Cosmo Pharmaceuticals NV was 0.45. The lowest was 0.01. And the median was 0.20.

XSWX:COPN's Debt-to-Equity is ranked worse than
58.78% of 849 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs XSWX:COPN: 0.41

Cosmo Pharmaceuticals NV Debt-to-Equity Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV Debt-to-Equity Chart

Cosmo Pharmaceuticals NV Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.36

0.42

0.34

0.38

Cosmo Pharmaceuticals NV Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Equity	Get a 7-Day Free Trial															0.45	0.34	0.37	0.38	0.41

Competitive Comparison of Cosmo Pharmaceuticals NV's Debt-to-Equity

For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cosmo Pharmaceuticals NV's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cosmo Pharmaceuticals NV's Debt-to-Equity falls into.

Cosmo Pharmaceuticals NV Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cosmo Pharmaceuticals NV's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(169.57	+	1.748)	/	450.925
	=	0.38

Cosmo Pharmaceuticals NV's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(169.893	+	1.358)	/	420.738
	=	0.41

Cosmo Pharmaceuticals NV (XSWX:COPN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cosmo Pharmaceuticals NV Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosmo Pharmaceuticals NV (XSWX:COPN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (XSWX:COPN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

CMOPF:USA COPNz:UK C43:Germany

Address

Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2

Website

https://www.cosmopharma.com

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (XSWX:COPN) Headlines

No Headlines